Do GLP-1 Drugs Cause Low Blood Sugar? Review of Hypoglycemia Risk | Research

The takeaway

While GLP-1 drugs were designed to work in a glucose-dependent manner (lower hypoglycemia risk), some evidence suggests they may cause low blood sugar in healthy normoglycemic individuals, prompting FDA safety evaluation of all 12 marketed GLP-1 agonists.

FDA safety evaluation
The FDA evaluated potential hypoglycemia safety signals across all 12 marketed GLP-1 receptor agonists after reports of low blood sugar in normoglycemic individuals

What the researchers found

GLP-1 receptor agonists were proposed to cause hypoglycemia in healthy normoglycemic subjects, challenging the assumption of purely glucose-dependent action. The FDA evaluated all 12 marketed GLP-1 RAs for potential hypoglycemia safety signals. Risk appears dependent on individual factors.

Why it matters

With GLP-1 drugs now widely prescribed for both diabetes and weight management in non-diabetic individuals, understanding their hypoglycemia risk — especially in people with normal blood sugar — is critically important for patient safety.

The numbers in context

12 GLP-1 drugs evaluated by FDA; some evidence of hypoglycemia in normoglycemic subjects; glucose-dependent mechanism questioned

How the study worked

Narrative review of clinical studies investigating GLP-1RA hypoglycemic effects, FDA safety evaluations, and adverse effect profiles.

Who was studied

Review covering healthy subjects and type 2 diabetes patients on GLP-1 receptor agonists

What this study cannot tell us

Narrative review with conflicting study conclusions. Hypoglycemia definitions vary across studies. Individual risk factors not well characterized. The distinction between clinically significant and asymptomatic hypoglycemia is important.

How to read the evidence

Not applicable (narrative review). Summarizes conflicting evidence and regulatory actions regarding GLP-1 drug hypoglycemia risk.

When this study was published

Published 2021. GLP-1 drug safety monitoring continues as use expands, with additional pharmacovigilance data accumulating.

The bigger picture

As GLP-1 drug use expands massively into weight management for non-diabetic populations, the hypoglycemia question becomes more relevant. Understanding the glucose-dependence limits of these drugs is essential for safe prescribing.

Questions still open

What individual factors determine hypoglycemia risk with GLP-1 drugs in non-diabetic patients?
Is the hypoglycemia risk different between different GLP-1 agonists?
Should blood sugar monitoring be recommended for non-diabetic patients on GLP-1 drugs for weight loss?

Common questions

Can Ozempic cause low blood sugar?

GLP-1 drugs were designed to lower blood sugar only when it's already high. However, some studies found they may occasionally cause low blood sugar even in people with normal glucose levels. The risk appears low but may depend on individual factors. Symptoms of low blood sugar include shakiness, sweating, and dizziness.

Should I worry about hypoglycemia if I take a GLP-1 drug for weight loss?

The risk appears to be low for most people. It's most important to eat regular meals, not skip eating, and be aware of low blood sugar symptoms. The risk is higher if you also take other blood sugar-lowering medications. Discuss with your doctor if you have concerns.

Read the original research

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia.

Clinical medicine insights. Endocrinology and diabetes, 14, 11795514211051697

View on PubMed ↗Publisher’s paper ↗

Citation

Ja'arah, Daria; Al Zoubi, Mazhar Salim; Abdelhady, Gamal; Rabi, Firas; Tambuwala, Murtaza M. (2021). Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia.. Clinical medicine insights. Endocrinology and diabetes, 14, 11795514211051697. https://doi.org/10.1177/11795514211051697